In addition, previous studies found that high tumor mutation burden (TMB) and PD-L1 expression, which were considered to predict better outcomes from immunotherapy, were more likely presented in patients with relatively shorter PFS to EGFR-TKI (16, 17). The gene discussed is EGFR; the disease is neoplasm.